This review highlights the emerging clinical utility of hs-CRP as a prognostic biomarker for cardiovascular risk assessment in primary prevention and acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
hs-CRP may refine risk stratification in primary prevention and ACS; leaves open whether targeting inflammation alters outcomes.
Benzaquen et al. (2002) studied this question.